



World Health
Organization

GUIDELINES



CONSOLIDATED GUIDELINES ON
**HIV PREVENTION, TESTING,
TREATMENT, SERVICE
DELIVERY AND MONITORING:**
RECOMMENDATIONS FOR A
PUBLIC HEALTH APPROACH

JULY 2021

CONSOLIDATED GUIDELINES ON
**HIV PREVENTION, TESTING,
TREATMENT, SERVICE
DELIVERY AND MONITORING:**

RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH

JULY 2021

Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach

This publication is the update of the Guidelines published in 2016 entitled "Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, 2nd ed".

ISBN 978-92-4-003159-3 (electronic version)

ISBN 978-92-4-003160-9 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

FOREWORD

As we enter the third decade of widespread delivery of HIV services across the world, the global AIDS response continues to make steady progress in saving lives and reducing the number of people infected with HIV.

These consolidated guidelines on preventing and treating HIV infection bring together a series of recommendations to promote the highest quality, person-centred delivery of care for people living with and affected by HIV. The proposed tools and approaches correspond to the best available standard of care for low-and middle-income countries, as well as for high-income countries – erasing any differences in the standards of care based on where a person lives.

HIV still causes too many avoidable deaths, but by providing the right health services in a timely manner, we can avoid the worst consequences of the virus. The recommendations in these guidelines aim to reduce the number of people dying from HIV and, when fully implemented, will help us to reach our goals of reducing global HIV deaths to less than 200,000 by 2030.

For most people living with HIV, it is a chronic, lifelong condition. Evidence and lived experience have shown that with the right support, people are able to manage their own health according to what works best in their lives.

The service delivery approaches put forward in these guidelines aim to promote self-management for the majority of people living with or affected by HIV. This includes an expanded range of options for diagnosing, preventing, and treating HIV that are delivered and monitored in the community.

It is only by supporting people living with HIV, and the communities they belong to, that the world can hope to end AIDS as a public health threat.

I hope you will join me in promoting these important new guidelines and support WHO's efforts to help countries move towards ending AIDS by 2030.



Dr Tedros Adhanom Ghebreyesus
Director-General
World Health Organization

A handwritten signature in blue ink, which appears to read "Tedros Adhanom". The signature is stylized and fluid.

CONTENTS

FOREWORD	III
ABBREVIATIONS AND ACRONYMS	VIII
ACKNOWLEDGEMENTS	XI
EXECUTIVE SUMMARY	XIII
SUMMARY RECOMMENDATIONS	XV
1. INTRODUCTION	1
1.1 Background and rationale	2
1.2 Objectives	2
1.3 Target audience	3
1.4 Guiding principles	3
1.5 Methods for developing the guidelines	4
1.6 Organization of the guidelines	5
2. HIV TESTING AND DIAGNOSIS	9
2.1 Introduction	10
2.2 HIV testing for a changing epidemic	10
2.3 Mobilizing demand and pre-test services	11
2.4 HIV testing service delivery approaches	14
2.5 Post-test services and linkage to prevention, treatment and other services	28
2.6 Strategies to make HIV testing services accessible	29
2.7 Maintaining the accuracy and reliability of HIV diagnosis	31
2.8 HIV diagnosis among infants and children	35
3. HIV PREVENTION	65
3.1 Combination HIV prevention	66
3.2 Pre-exposure prophylaxis for preventing the acquisition of HIV	68
3.3 Post-exposure prophylaxis	87
3.4 Infant prophylaxis	91

4. ANTIRETROVIRAL THERAPY	107
4.1 Introduction	108
4.2 Preparing people living with HIV for ART	108
4.3 What to expect in the first months of ART	109
4.4 When to start ART	110
4.5 Timing of ART	112
4.6 What to start	123
4.7 Monitoring the response to ART	147
4.8 Monitoring ARV toxicity	167
4.9 ARV drug resistance	179
4.10 Key ARV drug interactions	182
5. MANAGING ADVANCED HIV DISEASE	205
5.1 Introduction	206
5.2 Causes of morbidity and mortality among adults with advanced HIV disease	206
5.3 Providing a package of care	209
5.4 Overview of clinical management of cryptococcal disease	212
5.5 Overview of clinical management of histoplasmosis	216
5.6 Advanced HIV disease among children and adolescents	218
5.7 Supporting decision-making for providing a package of care	222
5.8 Programme considerations	224
6. GENERAL CARE AND MANAGING COMMON COINFECTIONS AND COMORBIDITIES	233
6.1 Introduction	234
6.2 General care for people living with HIV	234
6.3 Co-trimoxazole prophylaxis	239
6.4 Tuberculosis	245
6.5 Hepatitis B and C	261
6.6 Malaria	270
6.7 Buruli ulcer	271
6.8 Leishmaniasis	273

6.9	Cervical cancer	277
6.10	Noncommunicable diseases	283
6.11	Mental health among people living with HIV	286
6.12	Drug use	288
6.13	Sexually transmitted infections	289
6.14	Vaccines for people living with HIV	293
6.15	HIV-related skin and oral conditions	296
6.16	Nutritional care and support	297
6.17	Palliative care	302
6.18	Noncommunicable diseases among children and adolescents	306

7. SERVICE DELIVERY **339**

7.1	Introduction	340
7.2	Linkage from HIV testing to enrolment in care	342
7.3	Differentiated service delivery for HIV treatment	348
7.4	People-centred care	352
7.5	Initiating and maintaining treatment	354
7.6	Continuity of care	366
7.7	Task sharing	372
7.8	Decentralization	379
7.9	Integrating services	380
7.10	Delivering HIV services to children	391
7.11	Service delivery for adolescents	399
7.12	Improving the quality of HIV care services	410
7.13	Procurement and supply management systems for HIV health products	420
7.14	Laboratory and diagnostic services	434
7.15	Laboratory connectivity	438

8. MONITORING ART PROGRAMME FUNCTIONING	471
8.1 Introduction	472
8.2 Selection of key indicators to improve service delivery and assess impact	473
8.3 Data collection and disaggregation	475
8.4 Strengthening data systems	476
8.5 Evaluation, including impact and programme performance	478
8.6 Monitoring ARV drug toxicity	479
8.7 HIV drug resistance	481
9. PUBLICATION, DISSEMINATION AND EVALUATION	491
9.1 Publication	492
9.2 Dissemination and implementation	492
9.3 Useful analytical tools for planning	494
9.4 Evaluation	495
GLOSSARY	497
ANNEX 1: DOSAGES FOR ARV DRUGS	501
ANNEX 2: KEY DRUG INTERACTIONS FOR ARVS	519

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23706

